These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32417565)

  • 1. Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
    Xie S; Ye L; Ye X; Lin G; Xu RA
    J Pharm Biomed Anal; 2020 Aug; 187():113353. PubMed ID: 32417565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of UPLC-MS/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats.
    Shi L; Jiang Z; Zhang B; Tang C; Xu RA
    J Pharm Biomed Anal; 2020 Sep; 188():113386. PubMed ID: 32502954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS.
    Xia M; Liu YN; Chen J; Xu RA; Dai G
    Curr Med Chem; 2024; 31(34):5612-5619. PubMed ID: 38213178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Analysis of Fluconazole, Isavuconazole, Itraconazole, Hydroxy-Itraconazole, Posaconazole, and Voriconazole in Human Plasma and Serum.
    Müller C; Gehlen D; Blaich C; Prozeller D; Liss B; Streichert T; Wiesen MHJ
    Ther Drug Monit; 2017 Oct; 39(5):505-513. PubMed ID: 28742650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An LC-MS/MS Bioanalytical Assay for the Determination of Gilteritinib in Rat Plasma and Application to a Drug-Drug Interaction Study.
    Wang Q; Chen Z; Chen D; Ye XY
    Drug Des Devel Ther; 2020; 14():2061-2067. PubMed ID: 32546970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
    Dai D; Yang H; Nabhan S; Liu H; Hickman D; Liu G; Zacher J; Vutikullird A; Prakash C; Agresta S; Bowden C; Fan B
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1099-1108. PubMed ID: 31011758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study.
    Dittakavi S; Jat RK; Mullangi R
    Drug Res (Stuttg); 2019 Sep; 69(9):505-511. PubMed ID: 30822797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
    Shao Y; Xie S; Zhu H; Du X; Xu RA
    J Pharm Biomed Anal; 2020 Aug; 187():113355. PubMed ID: 32442869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
    Lou Y; Song F; Cheng M; Hu Y; Chai Y; Hu Q; Wang Q; Zhou H; Bao M; Gu J; Zhang Y
    PeerJ; 2023; 11():e15844. PubMed ID: 37581117
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Tang C; Niu X; Shi L; Zhu H; Lin G; Xu RA
    Front Pharmacol; 2020; 11():626897. PubMed ID: 33613287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
    Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
    Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma.
    Xiong X; Zhai S; Duan J
    Clin Chem Lab Med; 2013 Feb; 51(2):339-46. PubMed ID: 23095205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC-MS/MS assay.
    Zhang Y; Liu YN; Xie S; Xu X; Xu RA
    Pharm Biol; 2022 Dec; 60(1):621-626. PubMed ID: 35289238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid UPLC-MS/MS assay for the simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum.
    Basu SS; Petrides A; Mason DS; Jarolim P
    Clin Chem Lab Med; 2017 May; 55(6):836-844. PubMed ID: 27866173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC-MS/MS.
    Fu Y; Li Y; Ma Y; He X; Xun X; Cui Y; Fan L; Dong Z
    Biomed Chromatogr; 2023 Jan; 37(1):e5525. PubMed ID: 36241418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats.
    Chen M; Zhang X; Chen Y; Sun W; Wang Z; Huang C; Hu G; Chen R
    Xenobiotica; 2020 Mar; 50(3):280-287. PubMed ID: 31199171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential interactions between triazole antifungal agents and lorlatinib based on ultra-performance liquid chromatography-tandem mass spectrometry in rat plasma.
    Ye Z; Wang C; Li R; Chen C; Yang J; Chen Y; Fu J; Zhou T; Jin M; Huang A; Zhang X; Zhou Z
    J Pharm Pharmacol; 2024 Jan; 76(2):115-121. PubMed ID: 38150242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.